Blood testing startup Theranos came under scrutiny in 2012, long before the explosion of news about its technology this fall, according to the Washington Post.
Three years ago an official from the Department of Defense raised concerns that the company was violating the law. That led the DoD to launch an inquiry with the U.S. Food and Drug Administration to examine Theranos' tests, according to emails obtained by the Post.
At that time, CEO of the company, Elizabeth Holmes, asked that those "inaccurate" concerns be squelched, according to the newspaper.
Now the company is again finding itself in hot water after the Wall Street Journal released numerous reports that questioned the company's testing practices, and the U.S. Food and Drug Administration posted reports online after it determined that Theranos' collection containers are "uncleared medical devices" being used for interstate commerce. Article